| Revenue Growth | US Iptrosi $27.5M (18% growth); Collaboration/License $17.5M including $7.7M milestones/royalties. |
|---|---|
| Mgmt Confidence | High confidence in Iptrosi's 50-month DOR benchmark and Safusidenib's differentiated profile. |
| Demand Visibility | 60% market share in first-line starts; 160 new patients this quarter. |
| Margin Trends | Gross-to-net deductions stable at approximately 30%; Iptrosi now a self-sustaining program. |
| Op. Leverage | Iptrosi revenue run rate now covers its own launch-related operating expenses. |
| Vol vs Price | Growth driven by 18% sequential increase in active patient base. |
| Segment Growth | China and Japan launches exceeding expectations; US market leading in active patients. |
| New Clients | Major community pathway reinforced Iptrosi as primary first and second-line choice. |
| Capex & Debt | $663.4M cash balance; includes proceeds from December convertible debt offering. |
| Regulatory | FDA granted Fast Track designation for Safusidenib in IDH1 mutant glioma. |
| Commentary | Emphasized Iptrosi's lack of CNS warning vs competitors as key differentiator. |
| New Launches | Planning drug-drug conjugate (DDC) platform update and clinical entry by year-end. |
Growth
Total revenue $45M; Iptrosi US net revenue $27.5M, up 18% sequentially.
Outlook
Anticipated $30M milestone from European approval in 1H 2027; Safusidenib data expected in 2027.
Risks
15% decline in total ROS1 TKI market starts; management pivoted to 'lumpiness' without specific Q4 guidance.
The company's earnings call, NYSE: NUVB, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Nuvation Bio Inc.: key numbers
- Share price
- $3.84Close, Nov 16
- Market cap
- $1.36B
- Shares outstanding
- 353.02MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nuvation Bio Inc.
All →Nuvation Bio Financial Results
Nuvation Bio reported third quarter 2026 financial results, highlighted by $45.0 million in total revenue and $27.5 million in net product revenue for its ROS1 inhibitor IBTROZI. The company ended the quarter with $663.4 million in cash and marketable securities while achieving market leadership in new patient starts for ROS1+ NSCLC.
“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data.”
David Hung, M.D., Founder, President, and Chief Executive Officer
“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI’s durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy.”
David Hung, M.D., Founder, President, and Chief Executive Officer
Nuvation Bio Q3 2026 Results: Net Loss of $41.9M, Loss Narrows
Nuvation Bio Inc. reported financial results for the third quarter of 2026, highlighting continued progress in its clinical oncology programs. The company maintained a robust cash position to support operations through 2028, while reporting a net loss driven by ongoing research and development expenses.
- Key figure
- Net loss $41.9M